CompletedPHASE1, PHASE2NCT05443685
ADX-629 Therapy for Sjogren-Larsson Syndrome
Studying Autosomal ichthyosis syndrome with prominent neurologic signs
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Nebraska
- Principal Investigator
- William B Rizzo, MDUniversity of Nebraska
- Intervention
- ADX-629(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 5-50 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- University of Nebraska Medical Center, Omaha, Nebraska, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05443685 on ClinicalTrials.gov